MWN110
Clinical Trials

View on ClinicalTrials.gov
Development Highlights
1. ActRIIA/B-Targeted Approach: MWN110 is an investigational antibody targeting ActRIIA/B signaling, a pathway involved in skeletal muscle and adipose tissue biology.
2. Body Composition as a Clinical Focus: Its Phase 1 study evaluates body weight alongside exploratory measures of muscle mass, body fat percentage, and visceral and subcutaneous fat.
3. Potential to Increase Muscle Mass: MWN110 is being developed to explore its potential to increase skeletal muscle mass, with preclinical findings supporting further investigation.
For licensing and partnership inquiries, please contact us (bd@lepu-medical.com).
Thank You for Your Attention on Lepu Medical!
Email us with any questions or inquiries or use our contact data. We would be happy to answer your questions.
